Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conversion surgery after intraperitoneal paclitaxel plus capecitabine/oxaliplatin in advanced gastric cancer with peritoneal dissemination
KCT0005750Phase 2Not yet recruiting
- Sponsor
- Samyang Biopharmaceuticals Corporation
- Start
- Jan 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of paclitaxel, capecitabine, oxaliplatin in gastric adenocarcinoma, sponsored by Samyang Biopharmaceuticals Corporation. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
paclitaxelcapecitabineoxaliplatin
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on KCT0005750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005750.